Q BioMed Inc. (QBIO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 4.1 Million USD | 34.62% |
| 2021 | 3.05 Million USD | 3211.86% |
| 2020 | 92.18 Thousand USD | -97.5% |
| 2019 | 3.69 Million USD | 28.45% |
| 2018 | 2.87 Million USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 2.72 Million USD | 821.12% |
| 2015 | 296 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 4.08 Million USD | -0.65% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 3.41 Million USD | 2.07% |
| 2022 Q4 | 4.1 Million USD | 8.94% |
| 2022 Q3 | 3.77 Million USD | 10.46% |
| 2022 FY | 4.1 Million USD | 34.62% |
| 2022 Q1 | 3.34 Million USD | 9.6% |
| 2021 Q2 | 999.56 Thousand USD | 12.41% |
| 2021 FY | 3.05 Million USD | 3211.86% |
| 2021 Q4 | 3.05 Million USD | 156.49% |
| 2021 Q3 | 1.19 Million USD | 19.08% |
| 2021 Q1 | 889.17 Thousand USD | 864.56% |
| 2020 Q1 | 4.6 Million USD | 24.84% |
| 2020 Q4 | 92.18 Thousand USD | 2.32% |
| 2020 FY | 92.18 Thousand USD | -97.5% |
| 2020 Q2 | 96.68 Thousand USD | -97.9% |
| 2020 Q3 | 90.09 Thousand USD | -6.81% |
| 2019 Q4 | 3.69 Million USD | -17.28% |
| 2019 Q3 | 4.46 Million USD | 21.59% |
| 2019 Q2 | 3.66 Million USD | 17.0% |
| 2019 FY | 3.69 Million USD | 28.45% |
| 2019 Q1 | 3.13 Million USD | 9.16% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 2.87 Million USD | 0.0% |
| 2018 Q4 | 2.87 Million USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | - USD | -100.0% |
| 2017 Q3 | 2.06 Million USD | -31.41% |
| 2017 Q2 | 3 Million USD | 84.41% |
| 2017 Q1 | 1.62 Million USD | -40.23% |
| 2016 FY | 2.72 Million USD | 821.12% |
| 2016 Q1 | 941.05 Thousand USD | 217.93% |
| 2016 Q3 | 1.26 Million USD | 20.39% |
| 2016 Q2 | 1.05 Million USD | 11.59% |
| 2016 Q4 | 2.72 Million USD | 115.66% |
| 2015 FY | 296 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | 296 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Adynxx, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 90.524% |
| Qrons Inc. | 351.84 Thousand USD | -1068.116% |
| Skye Bioscience, Inc. | 4.61 Million USD | 10.948% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 86.193% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -552.298% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 90.979% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3255.087% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1225.8% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -15880.33% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 29.996% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 90.025% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 0.291% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -922.768% |
| SQZ Biotechnologies Company | 27.47 Million USD | 85.039% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -76.701% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -333.418% |
| Mesoblast Limited | 118.7 Million USD | 96.538% |
| Marizyme, Inc. | 18.71 Million USD | 78.042% |
| Genus plc | 233.1 Million USD | 98.237% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -40.254% |
| Pharming Group N.V. | 171.54 Million USD | 97.604% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -362.802% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -205.897% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -447.997% |
| ContraFect Corporation | 2.88 Million USD | -42.658% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2933.487% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -184.168% |
| IMV Inc. | 28.88 Million USD | 85.771% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 27.364% |
| MultiCell Technologies, Inc. | 202.58 USD | -2028718.738% |
| ONE Bio Corp. | 19.71 Million USD | 79.153% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 92.851% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -174.961% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 87.584% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -234.591% |
| Biomind Labs Inc. | 735.54 Thousand USD | -458.769% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 93.924% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -35.814% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 68.377% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1042.582% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2804.211% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -81.988% |
| GB Sciences, Inc. | 1.75 Million USD | -133.614% |
| Alpha Cognition Inc. | 1.22 Million USD | -236.781% |
| HST Global, Inc. | 98.31 Thousand USD | -4080.251% |
| CSL Limited | 12.18 Billion USD | 99.966% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1552.453% |
| Halberd Corporation | 150 Thousand USD | -2639.987% |
| Enzolytics Inc. | 996.33 Thousand USD | -312.509% |
| Agentix Corp. | 50 Thousand USD | -8119.962% |
| Resverlogix Corp. | 6.49 Million USD | 36.682% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1508.024% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 79.45% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 41.89% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -51.732% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -40095.413% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.016% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1948.681% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -71.412% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1692.474% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2664.797% |
| Kadimastem Ltd | 891.22 Thousand USD | -361.16% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 79.782% |
| BioStem Technologies, Inc. | 4.71 Million USD | 12.766% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1542.796% |
| LadRx Corporation | 33.6 Thousand USD | -12129.902% |
| Cell Source, Inc. | 9.25 Million USD | 55.588% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -443.502% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -443.502% |
| NovAccess Global Inc. | 2.19 Million USD | -86.828% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -1699.648% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1848.089% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 17.52% |
| Mobile Lads Corp. | 484.28 Thousand USD | -748.672% |
| CytoDyn Inc. | 30.07 Million USD | 86.335% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 47.442% |
| SYBLEU INC | 477.5 Thousand USD | -760.729% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 13.205% |
| International Stem Cell Corporation | 4.17 Million USD | 1.628% |
| Bioxytran, Inc. | 1.92 Million USD | -113.506% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6485.136% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -88.453% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 50.577% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 52.126% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -164.226% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1433.575% |
| Neutra Corp. | 54.15 Thousand USD | -7489.152% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -124.589% |
| PureTech Health plc | 25.51 Million USD | 83.89% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -235.721% |
| IXICO plc | 472.02 Thousand USD | -770.716% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 73.486% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 93.399% |
| CSL Limited | 12.18 Billion USD | 99.966% |
| Cellectis S.A. | 92.77 Million USD | 95.57% |